Phathom Pharmaceuticals, Inc. (PHAT) Stock Price & Analysis
Phathom Pharmaceuticals, Inc. (PHAT) fell 1.80% to USD 9.82 as of June 10, 2026 at 00:52 UTC, according to Nexqual real-time market data.
PHAT last closed at USD 10; the session ranged USD 9.79–10.23 on volume of 774,282 shares. Market capitalization is $783.20M, with a 52-week range of USD 7.61–18.31 (NMS). Source: Nexqual, June 10, 2026 at 00:52 UTC.
Key Statistics (as of June 10, 2026 at 00:52 UTC)
| Price | USD 9.82 |
|---|---|
| Change | ▼ 1.80% (down) |
| Previous Close | USD 10 |
| Open | USD 10.19 |
| Day Range | USD 9.79 – 10.23 |
| 52-Week Range | USD 7.61 – 18.31 |
| Volume | 774,282 shares |
| Market Cap | $783.20M |
| Exchange | NMS |
Technical Analysis (PHAT)
Nexqual's technical model rates PHAT "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:52 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.2 (neutral) |
| vs SMA50 | Below (USD 11.61) |
| MACD | -0.58 (negative) |
Analyst Ratings (PHAT)
Wall Street analysts rate PHAT "Strong Buy" based on 10 analysts, with a mean price target of USD 23.7 (range USD 13–29), per Nexqual as of June 10, 2026 at 00:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 23.7 |
| High Target | USD 29 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (PHAT)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $73.98M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.18 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.08 vs est -0.19 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.42 ▲ beat |
| 2025-06-30 | USD -0.79 vs est -0.92 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financials & Fundamentals (PHAT)
| Total Revenue | $204.89M |
|---|---|
| Revenue Growth (YoY) | +104.40% |
| Gross Margin | +84.93% |
| Operating Margin | -26.55% |
| Profit Margin | -76.77% |
| Current Ratio | 2.21 |
| Total Cash | $180.90M |
| Total Debt | $547.22M |
| Free Cash Flow | $-77.53M |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financial Health Score (PHAT)
Nexqual rates Phathom Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:52 UTC.
| Growth | Strong — Revenue +217% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 85%, operating -27% |
| Balance Sheet | Mixed — $181M cash vs $547M debt |
| Cash Flow | Weak — FCF negative: -$78M, burning cash |
| Efficiency | Mixed — No data |
Ownership (PHAT)
| Insider Ownership | +4.73% |
|---|---|
| Institutional Ownership | +88.45% |
| Shares Outstanding | 79.76M |
| Float | 60.35M |
| Short % of Float | +13.67% |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Leadership (PHAT)
Phathom Pharmaceuticals, Inc. is led by Steven L. Basta (age 59), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:52 UTC.
| CEO, President & Director | Steven L. Basta (age 59) |
|---|---|
| Chief Financial & Business Officer | Sanjeev Narula (age 63) |
| Director of Business Development & Investor Relations | Eric Sciorilli |
| Senior Vice President of Marketing & Analytics | Nancy R. Phelan (age 56) |
Major Backers & Investors (PHAT)
Notable institutional backers of Phathom Pharmaceuticals, Inc. include Frazier Life Sciences Management, L.P. , Medicxi Ventures Management (Jersey) Ltd, Invesco, according to Nexqual as of June 10, 2026 at 00:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 15.63% |
| Medicxi Ventures Management (Jersey) Ltd | 9.36% |
| Invesco | 5.42% |
| Millennium Management | 5.04% |
| Carlyle Group Inc. | 4.38% |
| AIM Intl Mutual Fd.s -Invesco Global Fd. | 2.94% |
| NEA Management Company, LLC | 2.46% |
| 683 Capital Management LLC | 2.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.44% |
| Vanguard Group | 6.4% |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
From Phathom Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
- It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
| TARS | Tarsus Pharmaceuticals, Inc. | USD 61.55 | ▲ 3.83% |
| ARQT | Arcutis Biotherapeutics, Inc. | USD 22.79 | ▲ 7.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:52 UTC. This page is informational and not investment advice.